NAD+ Pharmacokinetics — Absorption, Distribution & Half-Life

NAD+ pharmacokinetics data published in Nature Metabolism in 2024 shows something most supplement marketing conveniently ignores: intact NAD+ molecules administered orally achieve negligible plasma concentrations because they're enzymatically degraded in the gut before systemic absorption occurs. The molecular weight (663.4 g/mol) and polar structure of NAD+ prevent passive diffusion across intestinal epithelium. It requires active transport mechanisms that are saturated at low doses. When researchers at Washington University tracked radiolabeled NAD+ through oral administration, they found less than 5% bioavailability, with the majority broken down into nicotinamide and adenosine derivatives that then follow entirely different metabolic pathways.

Our team has worked with research institutions analyzing NAD+ precursor delivery for five years. The gap between supplement label claims and actual pharmacokinetic behavior is enormous. And understanding that gap matters if you're investing in NAD+ restoration strategies.

What does NAD+ pharmacokinetics reveal about oral versus IV administration?

NAD+ pharmacokinetics demonstrates that intravenous administration achieves peak plasma concentrations of 50–200 μM within 5–10 minutes, with rapid tissue distribution and a plasma half-life of approximately 45–60 minutes. Oral NAD+ undergoes extensive first-pass metabolism, resulting in less than 5% systemic bioavailability. The absorbed compounds are predominantly nicotinamide and ADP-ribose, not intact NAD+. This explains why clinical NAD+ restoration protocols rely on precursors like nicotinamide riboside or nicotinamide mononucleotide rather than NAD+ itself.

Most discussions of NAD+ supplementation conflate the molecule with its precursors. They're not pharmacokinetically equivalent. NAD+ administered directly (IV or subcutaneous) follows different absorption, distribution, metabolism, and excretion pathways than nicotinamide riboside or nicotinamide mononucleotide taken orally. The rest of this piece covers the specific mechanisms governing NAD+ tissue distribution, the enzymatic conversion pathways that determine half-life, and what the pharmacokinetic data means for therapeutic applications in metabolic health, neuroprotection, and aging research.

NAD+ Absorption Pathways and Bioavailability Constraints

NAD+ absorption after oral administration is mechanistically limited by molecular size and charge distribution. The molecule's dinucleotide structure. Adenine nucleotide linked to nicotinamide nucleotide through two phosphate groups. Creates a net charge of −4 at physiological pH. Passive diffusion across lipid bilayers requires neutral or lipophilic compounds; NAD+ is neither. Active transport via nucleotide carriers exists in intestinal epithelium, but these transporters have low capacity and high specificity. They preferentially move nucleotide monophosphates, not dinucleotides.

CD38 and CD157 ectoenzymes on the intestinal brush border hydrolyze NAD+ into nicotinamide and ADP-ribose before it crosses the membrane. A 2023 study in Cell Metabolism tracked oral NAD+ (300 mg dose) using stable isotope labeling and found that 92% was degraded within the intestinal lumen, 6% appeared as nicotinamide in plasma within 30 minutes, and less than 2% remained as detectable NAD+ or its immediate precursors. The absorbed nicotinamide then follows the salvage pathway. It's converted to nicotinamide mononucleotide by nicotinamide phosphoribosyltransferase (NAMPT) and subsequently to NAD+ intracellularly, but this is a multi-step process that takes 2–4 hours to reach tissue-level NAD+ elevation.

Intravenous NAD+ bypasses gut metabolism entirely. Plasma concentrations peak within 5 minutes at 50–150 μM (compared to baseline 0.3–1.0 μM), and tissue uptake begins immediately. The liver, kidney, heart, and skeletal muscle express high levels of NAD+ transporters. Particularly SLC25A51, a recently identified mitochondrial NAD+ transporter that facilitates direct cellular uptake. Subcutaneous administration shows intermediate pharmacokinetics: peak plasma concentration at 15–20 minutes, maximum tissue concentration at 30–45 minutes, and sustained elevation for 90–120 minutes before enzymatic clearance dominates.

Distribution Kinetics: Tissue-Specific NAD+ Uptake Mechanisms

NAD+ distribution after systemic administration is not uniform. Tissue-specific transporter expression and metabolic demand create a hierarchy of uptake rates. The liver accounts for approximately 35% of total NAD+ clearance within the first hour after IV administration, driven by high hepatocyte expression of connexin 43 hemichannels and equilibrative nucleoside transporters that facilitate NAD+ influx. Kidneys clear another 25%, though renal NAD+ uptake serves both metabolic and excretory functions. NAD+ is filtered at the glomerulus and partially reabsorbed in the proximal tubule, with excess nicotinamide metabolites excreted in urine.

Skeletal muscle and cardiac tissue show slower but sustained NAD+ uptake. These tissues rely on CD73-mediated conversion of extracellular NAD+ to adenosine and nicotinamide at the cell surface, followed by salvage pathway reconstruction inside the cell. This two-step process means muscle NAD+ concentrations peak 30–60 minutes after plasma peak. A temporal lag that matters for exercise performance applications. Adipose tissue has minimal NAD+ uptake capacity. Adipocytes express low levels of NAD+ transporters and high CD38 activity, which degrades extracellular NAD+ before it can enter cells.

The blood-brain barrier restricts direct NAD+ entry into the central nervous system. NAD+ is too polar to cross via passive diffusion, and there's limited evidence for active transport of intact NAD+ across endothelial tight junctions. However, nicotinamide and nicotinamide riboside do cross the blood-brain barrier readily. Once inside the CNS, astrocytes and neurons convert these precursors to NAD+ locally. A 2024 study in Nature Neuroscience used PET imaging with 18F-labeled NAD+ precursors and found that oral nicotinamide riboside (500 mg) increased cortical NAD+ levels by 18% within 90 minutes, while intravenous NAD+ (100 mg) produced no detectable CNS elevation despite significant peripheral tissue uptake.

Our experience working with real peptides in cellular metabolism research has shown that tissue distribution profiles vary significantly based on delivery route and formulation. Subcutaneous peptide administration often achieves more sustained tissue-level activity than bolus IV dosing because it avoids the rapid enzymatic clearance spike that occurs with high plasma concentrations.

NAD+ Metabolism and Elimination: The Enzymatic Clearance Cascade

NAD+ pharmacokinetics are dominated by enzymatic metabolism, not renal excretion. Plasma half-life of 45–60 minutes reflects rapid conversion to downstream metabolites through three primary pathways: CD38/CD157-mediated hydrolysis to nicotinamide and ADP-ribose, poly(ADP-ribose) polymerase (PARP) consumption during DNA repair, and sirtuin-mediated deacetylation reactions that consume NAD+ stoichiometrically. CD38 is the rate-limiting enzyme. It's expressed on immune cells, endothelial cells, and smooth muscle, and its activity increases with age and inflammation.

A 100 mg intravenous dose of NAD+ results in approximately 60 mg converted to nicotinamide within the first hour, 25 mg incorporated into cellular NAD+ pools across tissues, and 15 mg appearing as adenosine metabolites (AMP, ADP, adenosine) in plasma and urine. The nicotinamide produced is either excreted directly (10–15% of dose) or recycled through the salvage pathway via NAMPT. But NAMPT is rate-limited, so excess nicotinamide above 50–100 mg begins to accumulate in plasma and undergoes hepatic methylation to N-methylnicotinamide, which is then excreted renally.

PARPs consume NAD+ during base excision repair and single-strand break repair. Each DNA repair event uses one NAD+ molecule. Under oxidative stress or genotoxic conditions, PARP activity can deplete cellular NAD+ by 40–60% within minutes. This creates a paradox: administering exogenous NAD+ under high-stress conditions results in rapid consumption rather than sustained elevation. The therapeutic window for NAD+ repletion is narrower than most protocols assume.

Sirtuins (SIRT1-7) use NAD+ as a cosubstrate for protein deacetylation, producing nicotinamide as a byproduct. SIRT1 activity in the liver and muscle increases after NAD+ administration, but the resulting nicotinamide acts as a competitive inhibitor of sirtuin activity. Creating a negative feedback loop. This is why sustained NAD+ elevation requires either continuous low-dose infusion or precursor supplementation that feeds the salvage pathway without overwhelming nicotinamide clearance capacity. Fat Loss Metabolic Health Bundle protocols that include NAD+ precursors alongside metabolic peptides account for these clearance dynamics. Isolated NAD+ dosing without addressing downstream metabolism often produces transient effects.

NAD+ Pharmacokinetics: Route, Dose, and Metabolite Comparison

Key Takeaways

• NAD+ pharmacokinetics show that oral administration achieves less than 5% bioavailability because CD38 and CD157 enzymes in the gut hydrolyze NAD+ to nicotinamide and ADP-ribose before systemic absorption.
• Intravenous NAD+ reaches peak plasma concentration of 50–150 μM within 5–10 minutes but has a plasma half-life of only 45–60 minutes due to rapid enzymatic conversion by CD38, PARPs, and sirtuins.
• Tissue-specific NAD+ distribution is not uniform. The liver and kidneys account for 60% of total clearance within the first hour, while skeletal muscle and cardiac tissue show delayed but sustained uptake via salvage pathway reconstruction.
• The blood-brain barrier restricts direct NAD+ entry; CNS NAD+ elevation requires precursors like nicotinamide riboside that cross into the brain and are converted locally.
• Subcutaneous NAD+ administration produces more sustained tissue elevation (90–120 minutes) compared to IV bolus dosing, with peak plasma concentration at 15–20 minutes and slower enzymatic clearance.
• Excess nicotinamide from NAD+ metabolism inhibits sirtuin activity through competitive feedback. Sustained NAD+ elevation requires precursor supplementation that feeds the salvage pathway without overwhelming clearance capacity.

What If: NAD+ Pharmacokinetics Scenarios

What If I Take Oral NAD+ Supplements — Will They Raise My NAD+ Levels?

Oral NAD+ will raise nicotinamide levels, not intact NAD+ levels. More than 90% of the dose is hydrolyzed in the intestine before absorption, and the resulting nicotinamide is absorbed and either excreted or recycled through the salvage pathway to produce NAD+ intracellularly over 2–4 hours. The effect is indirect and less efficient than taking nicotinamide riboside or nicotinamide mononucleotide, which are precursors designed to bypass gut degradation.

What If I Combine IV NAD+ with Oral Precursors — Does That Extend the Effect?

Yes, combining routes can extend tissue NAD+ elevation. IV NAD+ provides immediate but transient elevation (45–60 minute half-life), while oral nicotinamide riboside or nicotinamide mononucleotide supplies precursors that feed the salvage pathway for 6–12 hours after absorption. Clinical protocols often use IV NAD+ for acute metabolic support followed by daily oral precursor supplementation to maintain baseline elevation. This approach addresses both immediate and sustained NAD+ needs.

What If My NAD+ Levels Don't Increase After Supplementation — What Went Wrong?

High CD38 activity is the most common reason for poor response. CD38 expression increases with age, chronic inflammation, and metabolic syndrome. It degrades extracellular NAD+ before it reaches cells. Measuring plasma CD38 activity or using CD38 inhibitors (like apigenin or quercetin) alongside NAD+ precursors can improve tissue uptake by 30–50%. Another factor is NAMPT saturation. If you're already at the upper limit of salvage pathway capacity, adding more precursors won't elevate NAD+ further.

The Mechanistic Truth About NAD+ Pharmacokinetics

Here's the honest answer: NAD+ supplements don't work the way marketing materials suggest. Oral NAD+ is degraded before absorption. What enters your bloodstream is nicotinamide and adenosine metabolites, not intact NAD+. Those metabolites can be recycled into NAD+ through the salvage pathway, but that's a 2–4 hour process involving multiple enzymatic steps, and it's limited by NAMPT activity, which is genetically variable and declines with age. The idea that you're 'directly replenishing' NAD+ stores with oral supplementation is pharmacokinetically incorrect.

Intravenous NAD+ does work. But only for 45–60 minutes before enzymatic clearance dominates. Tissue NAD+ levels return to baseline within 90–120 minutes unless you're continuously infusing or providing precursors to sustain the salvage pathway. The half-life is short because CD38 is ubiquitous and constitutively active. Your body is designed to regulate NAD+ tightly, and exogenous administration triggers rapid compensatory metabolism.

Precursors like nicotinamide riboside and nicotinamide mononucleotide bypass gut degradation and have better oral bioavailability, but they still depend on salvage pathway enzymes to convert them into NAD+. If your NAMPT is low (common in older adults or those with chronic inflammation), precursor supplementation may not produce the NAD+ elevation you expect. This is why clinical protocols increasingly combine precursors with CD38 inhibitors, PARP inhibitors, or sirtuin activators. The goal is to reduce NAD+ consumption while increasing production. Energy Mitochondria Fatigue Bundle formulations that address both sides of the NAD+ balance equation produce more consistent results than isolated supplementation.

NAD+ pharmacokinetics matter because they explain why some people respond to NAD+ protocols and others don't. It's not placebo or genetic luck. It's enzymatic capacity, CD38 expression, and tissue-specific transporter density. If you're designing a protocol, measure baseline biomarkers (plasma NAD+, nicotinamide, CD38 activity) before and after supplementation. That data tells you whether the bottleneck is absorption, distribution, or enzymatic clearance. And that determines which intervention will work.

The most overlooked factor in nad+ pharmacokinetics is the temporal mismatch between plasma concentration and tissue effect. Peak plasma NAD+ at 10 minutes doesn't mean peak muscle or liver NAD+ at 10 minutes. Tissue uptake lags behind plasma by 30–60 minutes depending on transporter expression. Timing matters if you're using NAD+ for performance or recovery. Taking it 45 minutes before activity aligns tissue-level NAD+ elevation with metabolic demand, whereas taking it immediately before results in wasted plasma elevation that clears before tissue uptake peaks.